Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)
Closed Solicitation Posted
- Solicitation number
- BAA-75N93026R00008
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases seeks research proposals for the Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB) program to accelerate tuberculosis vaccine development, with proposals due September 1, 2026, and questions due July 2, 2026. No set-aside applies; this is open competition.
Place of performance is the United States. The program requires characterization of tissue-specific and systemic protective immune responses against Mycobacterium tuberculosis infection and advancement of tools and resources for TB vaccine development, including biological models, new approach methodologies, organoids, in vitro systems, and computational modeling platforms. All proposals must incorporate human samples and/or clinical studies, at least one animal model, and computational data integration with cross-comparative analyses.
Awards will be made on a cost-reimbursement basis to educational institutions, nonprofit organizations, or research and development contractors, with anticipated two to three contracts. The NAICS code is 541715, Research and Development in the Physical, Engineering, and Life Sciences. Period of performance commences on the award date; base period cost and option period costs are to be determined.
Offerors must register in SAM prior to award and submit subcontracting plans included with the business proposal at submission (not through SBCX until invited to negotiate). The contract incorporates HHS and NIH policies on human subjects protection, clinical trial registration, financial conflict of interest, data sharing, reproducibility, animal welfare, and public access to research publications. Contractors must report via the eRA system and submit semi-annual technical progress reports. Each curriculum vitae is included in the page limit and may not exceed four pages; references are also page-limited. Foreign subcontractors and subsites are permitted without restrictions. Proposed budgets include $300,000 annually for cross-contract collaborative studies in years two through five, maximum three staff for scientific meeting attendance per contract year, and two total site visits across the contract life. Amendment No. 2 was issued July 21, 2026; offerors must acknowledge receipt on each proposal copy.
Notice text
3 versions
Update #3 · Latest ·
Amendment No. 2: BAA-75N93026R00008: The purpose of this Amendment is to provide responses to questions from potential offerors regarding the solicitation. Amendment No. 2 is attached below.
Amendment No. 1: BAA-75N93026R00008: The purpose of this Amendment is to provide responses to questions from potential offerors regarding the solicitation. Amendment No. 1 is attached below.
Please see the attached PDF for the solicitation notice (BAA-75N93026R00008).
Update #2 ·
Amendment No. 1: BAA-75N93026R00008: The purpose of this Amendment is to provide responses to questions from potential offerors regarding the solicitation. Amendment No. 1 is attached below.
Please see the attached PDF for the solicitation notice (BAA-75N93026R00008).
Update #1 ·
Please see the attached PDF for the solicitation notice (BAA-75N93026R00008).
Files
| File | Type | Posted |
|---|---|---|
| Amendment 2 RFP 75N93026R00008.pdf | ||
| Amendment 1 RFP 75N93026R00008.pdf | ||
| IMPAC-TB 75N93026R00008_Package.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Solicitation | |
| Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB) | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity